Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$16.27
+0.1%
$16.34
$10.99
$18.92
$5.80B0.59430,968 shs425,359 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$142.04
+3.5%
$116.05
$73.16
$146.75
$8.34B0.94779,321 shs532,593 shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€17.85
-0.1%
€15.38
€12.89
€28.00
€5.40B0.75662,160 shs366,432 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$62.04
-3.3%
$108.07
$60.10
$156.00
$2.14B2.071.07 million shs1.58 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+1.12%+1.27%-2.33%-3.22%+36.80%
Glaukos Corporation stock logo
GKOS
Glaukos
+0.56%+1.11%+14.93%+28.55%+48.78%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
-3.74%-7.60%+27.49%+12.71%-27.98%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
+0.39%-11.99%-43.38%-50.06%-47.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$16.27
+0.1%
$16.34
$10.99
$18.92
$5.80B0.59430,968 shs425,359 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$142.04
+3.5%
$116.05
$73.16
$146.75
$8.34B0.94779,321 shs532,593 shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€17.85
-0.1%
€15.38
€12.89
€28.00
€5.40B0.75662,160 shs366,432 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$62.04
-3.3%
$108.07
$60.10
$156.00
$2.14B2.071.07 million shs1.58 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+1.12%+1.27%-2.33%-3.22%+36.80%
Glaukos Corporation stock logo
GKOS
Glaukos
+0.56%+1.11%+14.93%+28.55%+48.78%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
-3.74%-7.60%+27.49%+12.71%-27.98%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
+0.39%-11.99%-43.38%-50.06%-47.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.21
Hold$18.0811.17% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.86
Moderate Buy$144.421.67% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.40
HoldN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.50
Moderate Buy$135.00117.60% Upside

Current Analyst Ratings Breakdown

Latest TMDX, GKOS, BLCO, and STVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Lower Price TargetBuy$152.00 ➝ $124.00
5/6/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Lower Price TargetBuy$190.00 ➝ $120.00
5/6/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Lower Price TargetHold$130.00 ➝ $85.00
5/6/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Lower Price TargetOverweight$160.00 ➝ $120.00
5/6/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Lower Price TargetBuy$174.00 ➝ $142.00
5/6/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
DowngradeOutperformMarket Perform
4/30/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Set Price Target$16.00
4/30/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Set Price Target$170.00
4/30/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetBuy$135.00 ➝ $140.00
4/30/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetOverweight$120.00 ➝ $140.00
4/30/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetOverweight$135.00 ➝ $138.00
(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$5.10B1.14$1.69 per share9.61$18.09 per share0.90
Glaukos Corporation stock logo
GKOS
Glaukos
$507.44M16.44N/AN/A$11.42 per share12.44
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€1.34B4.03€0.86 per share20.68€5.92 per share3.01
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$605.49M3.54$3.81 per share16.28$14.29 per share4.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$360M-$0.62N/A15.060.49-4.21%3.60%1.69%7/29/2026 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$187.69M-$3.28N/A302.22N/A-34.34%-6.92%-5.25%7/29/2026 (Estimated)
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€158.21M€0.5930.2522.031.6811.76%10.27%6.08%N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$190.29M$4.4014.1017.09N/A27.04%22.38%8.46%7/30/2026 (Estimated)

Latest TMDX, GKOS, BLCO, and STVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2026Q1 2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.12€0.11-€0.01€0.10N/A€273.57 million
5/5/2026Q1 2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.62$0.30-$0.32$0.20$174.44 million$173.93 million
4/29/2026Q1 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.08+$0.02-$0.20$1.22 billion$1.24 billion
4/29/2026Q1 2026
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.30-$0.18+$0.12-$0.34$137.00 million$150.57 million
2/18/2026Q4 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.35$0.32-$0.03-$0.16$1.38 billion$1.41 billion
2/17/2026Q4 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.22-$0.28-$0.06-$2.32$132.16 million$143.12 million
2/14/2026Q4 2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A€0.18N/A€0.17N/A€346.50 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/A1 Years
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.78
1.53
0.99
Glaukos Corporation stock logo
GKOS
Glaukos
0.10
5.43
4.73
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.21
1.63
1.11
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.70
6.74
6.19

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.45%
Glaukos Corporation stock logo
GKOS
Glaukos
5.80%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,000356.57 million351.40 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
1,09458.73 million55.33 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
6,010302.84 million300.72 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21034.56 million32.18 millionOptionable

Recent News About These Companies

TransMedics Group (TMDX) Gets a Buy from Needham
TransMedics tumbles after earnings miss

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$16.27 +0.02 (+0.10%)
Closing price 03:59 PM Eastern
Extended Trading
$15.96 -0.30 (-1.85%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Glaukos stock logo

Glaukos NYSE:GKOS

$142.04 +4.75 (+3.46%)
Closing price 03:59 PM Eastern
Extended Trading
$142.11 +0.07 (+0.05%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€17.84 -0.02 (-0.08%)
Closing price 03:59 PM Eastern
Extended Trading
€18.02 +0.18 (+0.98%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$62.04 -2.14 (-3.33%)
Closing price 04:00 PM Eastern
Extended Trading
$62.56 +0.52 (+0.84%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.